{"id":"bromfenac","rwe":[],"_fda":{"id":"08a05c09-5f0e-dca3-e063-6294a90a1bc1","set_id":"08a0591e-6cb3-30ce-e063-6394a90a33fb","openfda":{"upc":["0372485649716"],"unii":["8ECV571Y37"],"route":["OPHTHALMIC"],"rxcui":["578018"],"spl_id":["08a05c09-5f0e-dca3-e063-6294a90a1bc1"],"brand_name":["Bromfenac"],"spl_set_id":["08a0591e-6cb3-30ce-e063-6394a90a33fb"],"package_ndc":["72485-649-71"],"product_ndc":["72485-649"],"generic_name":["BROMFENAC"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["BROMFENAC SODIUM"],"manufacturer_name":["ARMAS PHARMACEUTICALS INC."],"application_number":["ANDA203395"],"is_original_packager":[true]},"version":"1","pregnancy":["8.1 Pregnancy Teratogenic Effects Pregnancy Category C Reproduction studies performed in rats at oral doses up to 0.9 mg/kg/day (1300 times the recommended human ophthalmic dose [RHOD]) and in rabbits at oral doses up to 7.5 mg/kg/day (11,000 times RHOD) revealed no evidence of teratogenicity due to bromfenac. However, 0.9 mg/kg/day in rats caused embryo-fetal lethality, increased neonatal mortality, and reduced postnatal growth. Pregnant rabbits treated with 7.5 mg/kg/day caused increased post-implantation loss. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac ophthalmic solution during late pregnancy should be avoided."],"description":["11 DESCRIPTION Bromfenac ophthalmic solution 0.09% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of bromfenac ophthalmic solution contains 1.035 mg bromfenac sodium (equivalent to 0.9 mg bromfenac free acid). Bromfenac sodium is designated chemically as sodium 2-amino-3-(4bromobenzoyl) phenylacetate sesquihydrate, with an empirical formula of C 15 H 11 BrNNaO 3 •1½H 2 O. The structural structure for bromfenac sodium is: Bromfenac sodium is a yellow to orange crystalline powder. The molecular weight of bromfenac sodium is 383.17. Bromfenac ophthalmic solution is supplied as a sterile aqueous 0.09% solution, with a pH of 8.3. The osmolality of bromfenac ophthalmic solution is approximately 300 mOsmol/kg. Each mL of bromfenac ophthalmic solution contains : Active: bromfenac sodium hydrate 0.1035% Preservative: benzalkonium chloride (0.05 mg/mL) Inactives: boric acid, disodium edetate, polysorbate 80, povidone K-30, purified water, sodium borate, and sodium sulfite anhydrous. Sodium hydroxide may be used to adjust pH. Chemical Structure_249"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Bromfenac Ophthalmic Solution 0.09% is supplied in a white LDPE plastic squeeze bottle with a LDPE white dropper-tip and polypropylene gray cap as follows: 1.7 mL in 6 mL container - 72485-649-71 STORAGE Store at 20º - 25ºC (68º - 77ºF) [see USP Controlled Room Temperature]."],"geriatric_use":["8.5 Geriatric Use There is no evidence that the efficacy or safety profiles for bromfenac differ in patients 65 years of age and older compared to younger adult patients."],"pediatric_use":["8.4 Pediatric Use Safety and efficacy in pediatric patients below the age of 18 have not been established."],"effective_time":"20231026","nursing_mothers":["8.3 Nursing Mothers Caution should be exercised when bromfenac is administered to a nursing woman."],"clinical_studies":["14 CLINICAL STUDIES 14.1 Ocular inflammation and pain following cataract surgery Clinical efficacy was evaluated in three randomized, double-masked, placebo-controlled trials in which subjects requiring cataract surgery were assigned to bromfenac or placebo. Patients were dosed with one drop per eye starting the day before surgery and continuing for 14 days. The primary endpoint was clearing of ocular inflammation by day 15. An additional efficacy endpoint was the number of patients who were pain free on day 1 after cataract surgery. In 2 of the 3 studies, bromfenac ophthalmic solution had statistically significant higher incidence of completely clearing inflammation (46-47% vs. 25-29%) and also had a statistically significant higher incidence of subjects that were pain free at day 1 post cataract surgery (83-89% vs. 51-71%)."],"pharmacokinetics":["12.3 Pharmacokinetics The plasma concentration of bromfenac following ocular administration of Bromfenac Ophthalmic Solution 0.09% in humans is unknown. Based on the maximum proposed dose of one drop to the eye (0.045 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans."],"adverse_reactions":["6 ADVERSE REACTIONS The most commonly reported adverse reactions in 2-7% of patients were abnormal sensation in eye, conjunctival hyperemia and eye irritation (including burning/stinging) (6.1) . To report SUSPECTED ADVERSE REACTIONS, contact Sentiss at 1-855-473-6847 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience The most commonly reported adverse experiences reported following use of bromfenac after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache, and iritis. These events were reported in 2-7% of patients. 6.2 Post-Marketing Experience The following events have been identified during post-marketing use of bromfenac ophthalmic solution 0.09% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical bromfenac ophthalmic solution 0.09% or a combination of these factors, include corneal erosion, corneal perforation, corneal thinning, and epithelial breakdown. [see Warnings and Precautions (5) ]"],"contraindications":["4 CONTRAINDICATIONS None."],"mechanism_of_action":["12.1 Mechanism of Action Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure."],"teratogenic_effects":["Teratogenic Effects Pregnancy Category C Reproduction studies performed in rats at oral doses up to 0.9 mg/kg/day (1300 times the recommended human ophthalmic dose [RHOD]) and in rabbits at oral doses up to 7.5 mg/kg/day (11,000 times RHOD) revealed no evidence of teratogenicity due to bromfenac. However, 0.9 mg/kg/day in rats caused embryo-fetal lethality, increased neonatal mortality, and reduced postnatal growth. Pregnant rabbits treated with 7.5 mg/kg/day caused increased post-implantation loss. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"storage_and_handling":["STORAGE Store at 20º - 25ºC (68º - 77ºF) [see USP Controlled Room Temperature]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. 12.3 Pharmacokinetics The plasma concentration of bromfenac following ocular administration of Bromfenac Ophthalmic Solution 0.09% in humans is unknown. Based on the maximum proposed dose of one drop to the eye (0.045 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans."],"indications_and_usage":["1 INDICATIONS AND USAGE Bromfenac Ophthalmic Solution 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction (1) ."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Sulfite Allergic Reactions (5.1) Slow or Delayed Healing (5.2) Potential for cross-sensitivity (5.3) Increase bleeding of ocular tissues (5.4) Corneal effects including keratitis (5.5) Contact Lens Wear (5.6) 5.1 Sulfite Allergic Reactions Contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. 5.2 Slow or Delayed Healing All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. 5.3 Potential for Cross-Sensitivity There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs. 5.4 Increased Bleeding Time With some NSAIDs, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. It is recommended that bromfenac ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. 5.5 Keratitis and Corneal Reactions Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health. Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post surgery may increase patient risk for the occurrence and severity of corneal adverse events. 5.6 Contact Lens Wear Bromfenac should not be administered while wearing contact lenses."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (900 times the recommended human ophthalmic dose [RHOD] of 1.67 mcg/kg in 60 kg person on a mg/kg/basis, assuming 100% absorbed) and 5 mg/kg/day (7500 times RHOD), respectively revealed no significant increases in tumor incidence. Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests. Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (1300 and 450 times RHOD, respectively)."],"nonteratogenic_effects":["Nonteratogenic Effects Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac ophthalmic solution during late pregnancy should be avoided."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION 17.1 Slowed or Delayed Healing Patients should be advised of the possibility that slow or delayed healing may occur while using NSAIDs. 17.2 Sterility of Dropper Tip Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents. 17.3 Concomitant Use of Contact Lenses Contact lenses should not be worn during the use of this product. 17.4 Concomitant Topical Ocular Therapy If more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart. Rx Only Distributed by: Armas Pharmaceuticals, Inc. Freehold, NJ 07728 USA Manufactured by: Ophtapharm AG Riethofstrasse 1, Hettlingen, 8442, Switzerland (CHE) for Sentiss Made in Switzerland Rev. 08/23"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery and through the first 14 days post-surgery (2.1) . 2.1 Recommended Dosing For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of bromfenac ophthalmic solution should be applied to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period. 2.2 Use with Other Topical Ophthalmic Medications Bromfenac ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart."],"spl_product_data_elements":["Bromfenac Bromfenac BORIC ACID EDETATE DISODIUM POLYSORBATE 80 POVIDONE K30 SODIUM BORATE SODIUM SULFITE SODIUM HYDROXIDE WATER BROMFENAC SODIUM BROMFENAC clear, yellow to orange yellow"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Topical ophthalmic solution: bromfenac 0.09%. Topical ophthalmic solution: bromfenac 0.09% (3)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Teratogenic Effects Pregnancy Category C Reproduction studies performed in rats at oral doses up to 0.9 mg/kg/day (1300 times the recommended human ophthalmic dose [RHOD]) and in rabbits at oral doses up to 7.5 mg/kg/day (11,000 times RHOD) revealed no evidence of teratogenicity due to bromfenac. However, 0.9 mg/kg/day in rats caused embryo-fetal lethality, increased neonatal mortality, and reduced postnatal growth. Pregnant rabbits treated with 7.5 mg/kg/day caused increased post-implantation loss. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac ophthalmic solution during late pregnancy should be avoided. 8.3 Nursing Mothers Caution should be exercised when bromfenac is administered to a nursing woman. 8.4 Pediatric Use Safety and efficacy in pediatric patients below the age of 18 have not been established. 8.5 Geriatric Use There is no evidence that the efficacy or safety profiles for bromfenac differ in patients 65 years of age and older compared to younger adult patients."],"package_label_principal_display_panel":["Package/Label Display Panel NDC 72485-649-71 Bromfenac Ophthalmic Solution 0.09% Once Daily For topical application in the eye. Rx only Sterile 1.7 mL container label carton label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (900 times the recommended human ophthalmic dose [RHOD] of 1.67 mcg/kg in 60 kg person on a mg/kg/basis, assuming 100% absorbed) and 5 mg/kg/day (7500 times RHOD), respectively revealed no significant increases in tumor incidence. Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests. Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (1300 and 450 times RHOD, respectively)."]},"tags":[{"label":"Nonsteroidal Anti-inflammatory Drug","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin G/H synthase 2","category":"target"},{"label":"PTGS2","category":"gene"},{"label":"PTGS1","category":"gene"},{"label":"S01BC11","category":"atc"},{"label":"Ophthalmic","category":"route"},{"label":"Solution/ Drops","category":"form"},{"label":"Suspension/ Drops","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Pain","category":"indication"},{"label":"Post-Op Ocular Inflammation","category":"indication"},{"label":"Postoperative Ocular Pain","category":"indication"},{"label":"Bausch And Lomb","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"173 reports"},{"date":"","signal":"EYE PAIN","source":"FDA FAERS","actionTaken":"167 reports"},{"date":"","signal":"TREATMENT FAILURE","source":"FDA FAERS","actionTaken":"152 reports"},{"date":"","signal":"EYE IRRITATION","source":"FDA FAERS","actionTaken":"145 reports"},{"date":"","signal":"VISION BLURRED","source":"FDA FAERS","actionTaken":"123 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"114 reports"},{"date":"","signal":"CATARACT","source":"FDA FAERS","actionTaken":"101 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"96 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"83 reports"},{"date":"","signal":"PRODUCT PACKAGING QUANTITY ISSUE","source":"FDA FAERS","actionTaken":"81 reports"}],"drugInteractions":[{"url":"/drug/lithium","drug":"lithium","action":"Monitor closely","effect":"May interact with Bromfenac Sodium, Lithium","source":"DrugCentral","drugSlug":"lithium"}],"commonSideEffects":[{"effect":"Conjunctival hyperemia","drugRate":"2-7%","severity":"mild","_validated":true},{"effect":"Eye irritation","drugRate":"2-7%","severity":"mild","_validated":true},{"effect":"Eye redness","drugRate":"2-7%","severity":"mild","_validated":true},{"effect":"Abnormal sensation in eye","drugRate":"2-7%","severity":"mild","_validated":true},{"effect":"Eye pain","drugRate":"2-7%","severity":"mild","_validated":true},{"effect":"Eye pruritus","drugRate":"2-7%","severity":"mild","_validated":true},{"effect":"Headache","drugRate":"2-7%","severity":"mild","_validated":true},{"effect":"Iritis","drugRate":"2-7%","severity":"mild","_validated":true}],"contraindications":["Diabetes mellitus","Epithelial Keratopathy","Red eye","Rheumatoid arthritis"],"specialPopulations":{"Lactation":"Caution should be exercised when PROLENSA ophthalmic solution is administered to nursing woman. There are no data on the presence of bromfenac in human milk, the effects on the breastfed infant, or the effects on milk production; however, systemic exposure to bromfenac from ocular administration is low.","Pregnancy":"There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of PROLENSA ophthalmic solution during late pregnancy should be avoided.","Geriatric use":"There is no evidence that the efficacy or safety profiles for bromfenac ophthalmic solution differ in patients 65 years of age and older compared to younger adult patients.","Paediatric use":"Safety and efficacy in pediatric patients below the age of 18 have not been established."}},"trials":[],"aliases":[],"company":"Bausch Health","patents":[{"applNo":"N203168","source":"FDA Orange Book","status":"Active","expires":"Nov 11, 2033","useCode":"U-1933","territory":"US","drugProduct":false,"patentNumber":"9517220","drugSubstance":false},{"applNo":"N203168","source":"FDA Orange Book","status":"Active","expires":"Nov 19, 2032","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10085958","drugSubstance":false}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$35.5129/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$12,785","description":"BROMFENAC SODIUM 0.09% EYE DRP","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BROMFENAC","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:17:20.640753+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:17:20.640250+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Bromfenac","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:17:28.178139+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:17:26.989298+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:17:19.228276+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BROMFENAC","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:17:27.616306+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:17:18.237664+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:17:18.237736+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:17:29.109471+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1077/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:17:28.071969+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA203395","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:17:18.237747+00:00"}},"allNames":"xibrom","offLabel":[],"synonyms":["yellox","bromfenac sodium sesquihydrate","prolensa","bromfenac","xibrom","bromfenac sodium"],"timeline":[{"date":"2005-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from BAUSCH AND LOMB INC to Bausch And Lomb"},{"date":"2005-03-24","type":"positive","source":"DrugCentral","milestone":"FDA approval (Bausch And Lomb Inc)"},{"date":"2016-04-08","type":"positive","source":"FDA Orange Book","milestone":"Bromsite approved — EQ 0.075% ACID"},{"date":"2023-08-15","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 10 manufacturers approved"}],"aiSummary":"Xibrom (BROMFENAC) is a nonsteroidal anti-inflammatory drug (NSAID) developed by Bausch and Lomb. It targets prostaglandin G/H synthase 2, a key enzyme involved in inflammation, and is used to treat pain, post-operative ocular inflammation, and postoperative ocular pain. Xibrom is a small molecule with a bioavailability of 67% and a half-life of 2.6 hours. It was FDA-approved in 2005 and is currently owned by Bausch and Lomb. Xibrom is available as a generic medication, with multiple manufacturers producing the drug.","brandName":"Xibrom","ecosystem":[{"indication":"Pain","otherDrugs":[{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"butorphanol","slug":"butorphanol","company":""},{"name":"caffeine","slug":"caffeine","company":"Novartis"},{"name":"choline magnesium trisalicylate","slug":"choline-magnesium-trisalicylate","company":""}],"globalPrevalence":1500000000},{"indication":"Post-Op Ocular Inflammation","otherDrugs":[{"name":"benzalkonium","slug":"benzalkonium","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"diclofenac","slug":"diclofenac","company":""}],"globalPrevalence":null},{"indication":"Postoperative Ocular Pain","otherDrugs":[{"name":"diclofenac","slug":"diclofenac","company":""},{"name":"difluprednate","slug":"difluprednate","company":"Alcon Pharms Ltd"},{"name":"ketorolac","slug":"ketorolac","company":""},{"name":"nepafenac","slug":"nepafenac","company":"Alcon Pharms Ltd"}],"globalPrevalence":null}],"mechanism":{"target":"Prostaglandin G/H synthase 2","novelty":"Follow-on","targets":[{"gene":"PTGS2","source":"DrugCentral","target":"Prostaglandin G/H synthase 2","protein":"Prostaglandin G/H synthase 2"},{"gene":"PTGS1","source":"DrugCentral","target":"Prostaglandin G/H synthase 1","protein":"Prostaglandin G/H synthase 1"}],"moaClass":"Cyclooxygenase Inhibitors","modality":"Small Molecule","drugClass":"Nonsteroidal Anti-inflammatory Drug","explanation":"Mechanism of Action. Bromfenac is nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity.The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.","oneSentence":"Xibrom works by blocking the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.","technicalDetail":"Xibrom selectively inhibits the enzyme prostaglandin G/H synthase 2 (COX-2), which is responsible for the production of prostaglandins in the body. By blocking this enzyme, Xibrom reduces the production of prostaglandins, leading to a decrease in pain and inflammation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Bromfenac","title":"Bromfenac","extract":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) marketed in the US as an ophthalmic solution by ISTA Pharmaceuticals for short-term, local use. Prolensa and Bromday are the once-daily formulation of bromfenac, while Xibrom was approved for twice-daily administration. In the European Union, the brand name is Yellox. Bromfenac is indicated for the treatment of ocular inflammation and pain after cataract surgery.","wiki_history":"== History ==\n\nFor ophthalmic use, bromfenac has been prescribed more than 20,000,000 times across the world. It was first FDA approved for use in the United States in 2005, and it was marketed as Xibrom, twice-daily. In October 2010 Bromday received US FDA approval as a new, once-daily formulation. In 2013, Prolensa has also been approved by the FDA.\n\nBromfenac was formerly marketed in the United States by Wyeth-Ayerst in an oral formulation called Duract for short-term relief of pain (less than 10 days at a time). It was brought to market in July 1997, and was withdrawn 22 June 1998, following numerous reports of hepatotoxicity in patients who had taken the medication for longer than the recommended 10-day period."},"commercial":{"launchDate":"2005","_launchSource":"DrugCentral (FDA 2005-03-24, BAUSCH AND LOMB INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/401","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BROMFENAC","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BROMFENAC","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Bromfenac","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:02:47.276513","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:17:34.408491+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"indomethacin","drugSlug":"indomethacin","fdaApproval":"1965-06-10","patentExpiry":"Apr 23, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"oxyphenbutazone","drugSlug":"oxyphenbutazone","fdaApproval":"1960-12-21","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"diclofenac","drugSlug":"diclofenac","fdaApproval":"1988-07-28","patentExpiry":"Apr 23, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"flurbiprofen","drugSlug":"flurbiprofen","fdaApproval":"1986-12-31","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ketorolac","drugSlug":"ketorolac","fdaApproval":"1989-11-30","patentExpiry":"Nov 24, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"piroxicam","drugSlug":"piroxicam","fdaApproval":"1982-04-06","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nepafenac","drugSlug":"nepafenac","fdaApproval":"2005-08-19","patentExpiry":"Mar 31, 2032","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"bromfenac","indications":{"approved":[{"name":"Pain","source":"DrugCentral","snomedId":22253000,"regulator":"FDA","eligibility":"patients who have undergone cataract extraction","usPrevalence":51600000,"globalPrevalence":1500000000,"prevalenceMethod":"curated","prevalenceSource":"CDC, 2023"},{"name":"Post-Op Ocular Inflammation","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"patients who have undergone cataract extraction"},{"name":"Postoperative Ocular Pain","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"patients who have undergone cataract extraction"}],"offLabel":[],"pipeline":[]},"currentOwner":"Bausch And Lomb","drugCategory":"mature","labelChanges":[],"relatedDrugs":[{"drugId":"indomethacin","brandName":"indomethacin","genericName":"indomethacin","approvalYear":"1965","relationship":"same-class"},{"drugId":"oxyphenbutazone","brandName":"oxyphenbutazone","genericName":"oxyphenbutazone","approvalYear":"1960","relationship":"same-class"},{"drugId":"diclofenac","brandName":"diclofenac","genericName":"diclofenac","approvalYear":"1988","relationship":"same-class"},{"drugId":"flurbiprofen","brandName":"flurbiprofen","genericName":"flurbiprofen","approvalYear":"1986","relationship":"same-class"},{"drugId":"ketorolac","brandName":"ketorolac","genericName":"ketorolac","approvalYear":"1989","relationship":"same-class"},{"drugId":"piroxicam","brandName":"piroxicam","genericName":"piroxicam","approvalYear":"1982","relationship":"same-class"},{"drugId":"nepafenac","brandName":"nepafenac","genericName":"nepafenac","approvalYear":"2005","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":["Corneal Edema","Corneal Defect","Anterior Chamber Inflammation","Ocular Pain","Corneal Staining","Visual Outcome","CME - Cystoid Macular Edema"],"enrollment":50,"completionDate":"2025-02-05"},{"nctId":"NCT07178639","phase":"NA","title":"Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery","status":"RECRUITING","sponsor":"Nemocnice Kolín","startDate":"2025-08-01","conditions":["Macular Oedema","Cataract Surgery","NSAID (Non-Steroidal Anti-Inflammatory Drug)"],"enrollment":150,"completionDate":"2026-02-28"},{"nctId":"NCT07090044","phase":"PHASE4","title":"Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period","status":"COMPLETED","sponsor":"Retina Research Institute, LLC","startDate":"2021-08-20","conditions":["Vein Occlusion","Macular Degeneration Choroidal Neovascularization","Macular Edema","Diabetic Retinopathy"],"enrollment":77,"completionDate":"2022-12-08"},{"nctId":"NCT03317847","phase":"PHASE4","title":"Bromfenac Versus Dexamethasone After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2017-10-16","conditions":["Inflammation Eye"],"enrollment":92,"completionDate":"2019-12-21"},{"nctId":"NCT02137161","phase":"PHASE4","title":"Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2013-11","conditions":["Cataract","Pseudoexfoliation Syndrome"],"enrollment":62,"completionDate":"2014-10"},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":["Cataract","Cystoid Macular Edema After Phacoemulsification"],"enrollment":87,"completionDate":"2024-01-31"},{"nctId":"NCT05158699","phase":"PHASE3","title":"Effectiveness of Periocular Drug Injection in CATaract Surgery","status":"TERMINATED","sponsor":"Luigi Rondas","startDate":"2021-10-13","conditions":["Macular Edema","Cystoid Macular Edema","Retinal Disease","Cataract","Lens Diseases","Eye Diseases"],"enrollment":628,"completionDate":"2024-08-13"},{"nctId":"NCT06130384","phase":"PHASE4","title":"Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2021-03-01","conditions":["Pain","Intravitreal Injection","Pain, Acute"],"enrollment":97,"completionDate":"2023-11-15"},{"nctId":"NCT05107921","phase":"PHASE2","title":"Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2021-11-01","conditions":["Familial Exudative Vitreoretinopathies"],"enrollment":39,"completionDate":"2024-10-20"},{"nctId":"NCT04343222","phase":"PHASE4","title":"Control of Pain in Intravitreal Injections Using Topical NSAIDs","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-06-27","conditions":["Intravitreal Injections","IVI"],"enrollment":46,"completionDate":"2019-12-19"},{"nctId":"NCT05665270","phase":"PHASE4","title":"A Study for Post op Inflammation After Cataract Surgery","status":"UNKNOWN","sponsor":"Wyse Eyecare","startDate":"2023-01-30","conditions":["Cataract"],"enrollment":40,"completionDate":"2023-12-15"},{"nctId":"NCT05715385","phase":"PHASE4","title":"Comparison of Treatments in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Babasaheb Ambedkar Memorial Hospital","startDate":"2014-11","conditions":["Diabetic Macular Edema"],"enrollment":60,"completionDate":"2015-10"},{"nctId":"NCT03578276","phase":"PHASE4","title":"Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2018-06-22","conditions":["Cataract"],"enrollment":35,"completionDate":"2019-12-04"},{"nctId":"NCT04940338","phase":"PHASE4","title":"PCME Prevention in Patients With NPDR","status":"COMPLETED","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-05-01","conditions":["Cystoid Macular Edema Following Cataract Surgery"],"enrollment":90,"completionDate":"2022-01-01"},{"nctId":"NCT01808547","phase":"PHASE3","title":"Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2013-05","conditions":["Ocular Inflammation"],"enrollment":268,"completionDate":"2013-11"},{"nctId":"NCT01190878","phase":"PHASE1,PHASE2","title":"Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2010-08","conditions":["Ocular Inflammation"],"enrollment":169,"completionDate":"2011-01"},{"nctId":"NCT01478555","phase":"PHASE2","title":"A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2018-01","conditions":["Dry Eye Disease"],"enrollment":0,"completionDate":"2019-01"},{"nctId":"NCT01387464","phase":"PHASE2","title":"Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2011-07","conditions":["Cataract"],"enrollment":60,"completionDate":"2011-08"},{"nctId":"NCT01576952","phase":"PHASE3","title":"Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2012-07","conditions":["Ocular Inflammation"],"enrollment":268,"completionDate":"2013-01"},{"nctId":"NCT05006898","phase":"PHASE1","title":"Compound to Control Presbyopia Symptoms","status":"COMPLETED","sponsor":"Optall Vision","startDate":"2020-06-01","conditions":["Presbyopia"],"enrollment":11,"completionDate":"2020-07-01"},{"nctId":"NCT05001243","phase":"PHASE1","title":"Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients","status":"UNKNOWN","sponsor":"Optall Vision","startDate":"2021-08-10","conditions":["Presbyopia"],"enrollment":11,"completionDate":"2021-09-10"},{"nctId":"NCT05006911","phase":"PHASE1","title":"Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms","status":"UNKNOWN","sponsor":"Optall Vision","startDate":"2021-08-14","conditions":["Presbyopia"],"enrollment":11,"completionDate":"2021-09-15"},{"nctId":"NCT04273282","phase":"PHASE4","title":"A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2019-12-16","conditions":["Cataract"],"enrollment":31,"completionDate":"2020-11-24"},{"nctId":"NCT01310127","phase":"PHASE4","title":"Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2010-11","conditions":["Inflammation","Pseudophakia"],"enrollment":23,"completionDate":"2011-05"},{"nctId":"NCT03751059","phase":"PHASE4","title":"NSAID vs Steroid in Trabeculectomy Wound Management","status":"UNKNOWN","sponsor":"Cindy Hutnik","startDate":"2020-11","conditions":["Glaucoma"],"enrollment":150,"completionDate":"2021-12"},{"nctId":"NCT00758784","phase":"PHASE2","title":"Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-08-13","conditions":["Dry Eye Disease"],"enrollment":38,"completionDate":"2009-01-14"},{"nctId":"NCT01212471","phase":"PHASE3","title":"A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-09","conditions":["Dry Eye Syndrome"],"enrollment":840,"completionDate":"2011-12"},{"nctId":"NCT03521791","phase":"PHASE4","title":"Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-12-13","conditions":["Pterygium","Ocular Pain","Ocular Inflammation","Post-surgical Inflammation"],"enrollment":166,"completionDate":"2018-10-31"},{"nctId":"NCT01535443","phase":"PHASE1","title":"Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2011-09","conditions":["Inflammation","Cataract"],"enrollment":35,"completionDate":"2011-10"},{"nctId":"NCT04022811","phase":"PHASE4","title":"Effect of Bromfenac on Pain Related to Pterygium Surgery","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2016-10","conditions":["Pterygium","Pain"],"enrollment":60,"completionDate":"2017-10"},{"nctId":"NCT03886779","phase":"PHASE4","title":"Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial","status":"COMPLETED","sponsor":"Silverstein Eye Centers","startDate":"2013-10-30","conditions":["Treatment of Ocular Inflammation Associated With Cataract Surgery"],"enrollment":57,"completionDate":"2019-03"},{"nctId":"NCT03831984","phase":"PHASE4","title":"Topical Bromfenac for Intraoperative Miosis and Pain Reduction","status":"UNKNOWN","sponsor":"Hospital de La Luz","startDate":"2018-03-01","conditions":["Cataract"],"enrollment":60,"completionDate":"2019-03-30"},{"nctId":"NCT02973880","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction","status":"COMPLETED","sponsor":"SIFI SpA","startDate":"2017-10-15","conditions":["Cataract Extraction","Cataract"],"enrollment":180,"completionDate":"2018-12-30"},{"nctId":"NCT01847638","phase":"NA","title":"Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery","status":"COMPLETED","sponsor":"Melissa Toyos","startDate":"2013-04-01","conditions":["Cataract","Retinal Edema","Inflammation"],"enrollment":50,"completionDate":"2018-08-23"},{"nctId":"NCT01657266","phase":"PHASE2","title":"Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2013-12","conditions":["Cataract","Phacoemulsification Cataract Surgery"],"enrollment":160,"completionDate":"2015-04"},{"nctId":"NCT01189864","phase":"","title":"Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas","status":"TERMINATED","sponsor":"Cxlusa","startDate":"2010-02-01","conditions":["Keratoconus","Ectasia","Degeneration"],"enrollment":3493,"completionDate":"2017-02-03"},{"nctId":"NCT01024322","phase":"","title":"Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas","status":"TERMINATED","sponsor":"Cxlusa","startDate":"2009-10-01","conditions":["Keratoconus","Ectasia","Degeneration"],"enrollment":1189,"completionDate":"2017-02-03"},{"nctId":"NCT01097447","phase":"","title":"Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)","status":"TERMINATED","sponsor":"Cxlusa","startDate":"2009-12-01","conditions":["Keratoconus","Ectasia","Degeneration"],"enrollment":2619,"completionDate":"2017-04-30"},{"nctId":"NCT03597867","phase":"PHASE3","title":"PGE2 Levels in Patient Treated With NSAIDs","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2018-04-25","conditions":["Ocular Inflammation"],"enrollment":104,"completionDate":"2018-07-09"},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":["Cystoid Macular Edema","Cataract","Diabetes Mellitus"],"enrollment":1127,"completionDate":"2016-11-04"},{"nctId":"NCT03106402","phase":"","title":"Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2013-10-01","conditions":["Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification"],"enrollment":316,"completionDate":"2015-07-30"},{"nctId":"NCT00438243","phase":"PHASE2","title":"Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2008-05","conditions":["Cystoid Macular Edema"],"enrollment":0,"completionDate":"2010-09"},{"nctId":"NCT01475877","phase":"","title":"Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy","status":"COMPLETED","sponsor":"Virdi Eye Clinic","startDate":"2011-05","conditions":["Myopia"],"enrollment":20,"completionDate":"2012-05"},{"nctId":"NCT02681679","phase":"NA","title":"Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-10","conditions":["Cataract"],"enrollment":60,"completionDate":"2015-12"},{"nctId":"NCT00703781","phase":"PHASE3","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":["Cataract"],"enrollment":126,"completionDate":""},{"nctId":"NCT02361645","phase":"PHASE3","title":"NSAIDs and PGE2 Levels in Vitrectomy Patients","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2014-03","conditions":["Vitreous Inflammation"],"enrollment":70,"completionDate":"2015-01"},{"nctId":"NCT01367249","phase":"PHASE3","title":"Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-05","conditions":["Pain","Inflammation","Cataract"],"enrollment":440,"completionDate":"2011-12"},{"nctId":"NCT00423007","phase":"PHASE3","title":"Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":["Allergic Conjunctivitis"],"enrollment":90,"completionDate":"2007-08"},{"nctId":"NCT00198445","phase":"PHASE3","title":"Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2003-05","conditions":["Postoperative Complications","Cataract"],"enrollment":527,"completionDate":"2004-01"},{"nctId":"NCT00585975","phase":"PHASE2","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-10","conditions":["Cataract Surgery"],"enrollment":568,"completionDate":""},{"nctId":"NCT00333918","phase":"PHASE3","title":"Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":["Pain","Inflammation"],"enrollment":522,"completionDate":"2007-03"},{"nctId":"NCT00853970","phase":"PHASE3","title":"Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":["Pain","Inflammation"],"enrollment":299,"completionDate":"2009-12"},{"nctId":"NCT00704418","phase":"PHASE3","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":["Cataract"],"enrollment":156,"completionDate":"2009-12"},{"nctId":"NCT01193504","phase":"PHASE4","title":"Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification","status":"UNKNOWN","sponsor":"Innovative Medical","startDate":"2010-09","conditions":["Pseudophakia","Cataract Surgery"],"enrollment":100,"completionDate":"2012-10"},{"nctId":"NCT00758199","phase":"PHASE4","title":"Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-07","conditions":["Cataracts"],"enrollment":49,"completionDate":"2010-01"},{"nctId":"NCT01001806","phase":"PHASE4","title":"A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2009-10","conditions":["Cataracts"],"enrollment":126,"completionDate":"2010-01"},{"nctId":"NCT01021761","phase":"PHASE4","title":"A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2009-10","conditions":["Cataracts"],"enrollment":126,"completionDate":"2010-01"},{"nctId":"NCT01023724","phase":"PHASE4","title":"A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)","status":"COMPLETED","sponsor":"Bucci Laser Vision Institute","startDate":"2009-12","conditions":["Post Operative Anterior Chamber Inflammation (Flare)"],"enrollment":50,"completionDate":"2010-02"},{"nctId":"NCT00805233","phase":"PHASE2","title":"Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2008-12","conditions":["Age-Related Macular Degeneration"],"enrollment":30,"completionDate":"2010-09"},{"nctId":"NCT00758628","phase":"PHASE4","title":"Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-08","conditions":["Diabetic Macular Edema"],"enrollment":50,"completionDate":"2009-05"},{"nctId":"NCT00828477","phase":"PHASE4","title":"Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2009-01","conditions":["Intraocular Pressure"],"enrollment":25,"completionDate":"2009-06"},{"nctId":"NCT00698724","phase":"PHASE4","title":"Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":["Cataracts"],"enrollment":200,"completionDate":"2009-06"},{"nctId":"NCT00595543","phase":"PHASE4","title":"Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-01","conditions":["Acute Pseudophakic Cystoid Macular Edema"],"enrollment":166,"completionDate":"2009-03"},{"nctId":"NCT00520260","phase":"PHASE4","title":"Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase","status":"COMPLETED","sponsor":"Florida Eye Microsurgical Institute","startDate":"2007-08","conditions":["Dry Eye Disease","Ocular Comfort"],"enrollment":42,"completionDate":"2008-08"},{"nctId":"NCT00377546","phase":"PHASE4","title":"Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":["Vitrectomy"],"enrollment":0,"completionDate":""},{"nctId":"NCT00469781","phase":"PHASE4","title":"Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening","status":"COMPLETED","sponsor":"Center For Excellence In Eye Care","startDate":"2007-05","conditions":["Cystoid Macular Edema,","Retinal Thickening"],"enrollment":95,"completionDate":"2008-09"},{"nctId":"NCT00469690","phase":"PHASE4","title":"Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"2007-05","conditions":["Cataract"],"enrollment":58,"completionDate":"2008-05"},{"nctId":"NCT00347503","phase":"PHASE4","title":"Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":["Cataract"],"enrollment":0,"completionDate":""},{"nctId":"NCT00491166","phase":"PHASE1","title":"Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2007-06","conditions":["Diabetic Macular Edema"],"enrollment":10,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic","formulation":"Solution/ Drops, Suspension/ Drops","formulations":[{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"BROMFENAC"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Bromfenac"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Bromfenac Ophthalmic Solution 0.09%"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"bromfenac"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"BROMSITE0.075%"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Bromday"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Prolensa"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Pred Phos - Brom"},{"form":"SUSPENSION/ DROPS","route":"OPHTHALMIC","productName":"Pred-Brom"},{"form":"SUSPENSION/ DROPS","route":"OPHTHALMIC","productName":"Pred-Gati-Brom"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"181436","NDDF":"006757","UNII":"864P0921DW","CHEBI":"CHEBI:240107","VANDF":"4021048","INN_ID":"5892","RXNORM":"1375918","UMLSCUI":"C0054094","chemblId":"CHEMBL1077","ChEMBL_ID":"CHEMBL1077","KEGG_DRUG":"D07541","DRUGBANK_ID":"DB00963","PDB_CHEM_ID":" 27R","PUBCHEM_CID":"60726","SNOMEDCT_US":"108520008","IUPHAR_LIGAND_ID":"7131","SECONDARY_CAS_RN":"120638-55-3","MESH_SUPPLEMENTAL_RECORD_UI":"C053083"},"formularyStatus":[],"originalProduct":{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","company":"Bausch & Lomb Incorporated","brandName":"Prolensa","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2005-","companyName":"Bausch And Lomb Inc","relationship":"Original Developer"},{"period":"present","companyName":"Bausch And Lomb","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.6 hours","clearance":"1.3 mL/min/kg","bioavailability":"67%","fractionUnbound":"0.0011%","volumeOfDistribution":"0.11 L/kg"},"publicationCount":307,"therapeuticAreas":["Ophthalmology"],"atcClassification":{"source":"DrugCentral","atcCode":"S01BC11","allCodes":["S01BC11"]},"biosimilarFilings":[],"originalDeveloper":"Bausch And Lomb Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":11,"_genericFilersChecked":true,"genericManufacturerList":["Alembic","Amneal","Amring Pharms","Apotex","Chartwell Rx","Coastal Pharms","Eugia Pharma","Gland","Lupin Ltd","Rising","Sentiss"],"status":"withdrawn","companyName":"Bausch And Lomb","companyId":"bausch","modality":"Small molecule","firstApprovalDate":"2005","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-01-22T00:00:00.000Z","mah":"SENTISS","brand_name_local":null,"application_number":"ANDA203395"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-04-08T00:00:00.000Z","mah":"SUN PHARM","brand_name_local":null,"application_number":"NDA206911"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-06-21T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":null,"application_number":"ANDA210560"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-02-02T00:00:00.000Z","mah":"LUPIN LTD","brand_name_local":null,"application_number":"ANDA211239"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-07-08T00:00:00.000Z","mah":"APOTEX","brand_name_local":null,"application_number":"ANDA207334"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":"EMEA/H/C/001198"},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Yellox","application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:17:34.408491+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}